2026 Annual Meeting | PL5 - Clinical Trials Plenary Session

Date Tuesday 04/21/26

Time 09:15 AM - 11:30 AM CDT Add To Calendar

Location McCormick Place West | W375de

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) H. E. Hinson, MD, MCR, FAAN, Vijay K. Ramanan, MD, PhD, FAAN

Topic(s) General Neurology, Movement Disorders, Neuromuscular and Clinical Neurophysiology (EMG), Aging, Dementia, and Behavioral Neurology, Multiple Sclerosis, Neuro Trauma and Critical Care

Learning Objectives This session covers landmark clinical trials that affect patient care in every subspecialty of neurology. Investigators will present the latest clinical trials results that are impacting the landscape of neurological care.

CME Available 2.25 CME credits

Program Tracks Medical Students, Residents

Program Materials Program Evaluations

Event Timeline
09:15 AM - 09:30 AM CDT	Speaker	Maintenance of Response and Durability of Effect with Ulixacaltamide in Essential Tremor: Topline Phase 3 Results from Essential3 Study 2 (Randomized Withdrawal Study) Jill M. Farmer, DO, MPH
09:30 AM - 09:45 AM CDT	Speaker	Rapid and Sustained Efficacy of Subcutaneously Administered Cemdisiran Without Complete Complement Blockade in Patients with Generalized Myasthenia Gravis (gMG): Primary Efficacy and Safety Results from the Phase Three NIMBLE Trial Tuan H. Vu, MD
09:45 AM - 10:00 AM CDT	Speaker	Efficacy and Safety of Zilganersen, an Investigational RNA-targeted Antisense Therapy, in People Living with Alexander Disease: Results from a Pivotal Study Amy T. Waldman, MD
10:00 AM - 10:15 AM CDT	Speaker	Efficacy and Safety of Ecopipam for Tourette Syndrome: Results from a Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Trial Kinga Tomczak, MD, PhD
10:15 AM - 10:30 AM CDT	Speaker	Improved Low Contrast Visual Acuity, Reduction in Retinal Ganglion Cell Loss, and Neurofilaments-light with Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Placebo-controlled, Double-masked Trial Pablo Villoslada, MD, PhD, FAAN
10:30 AM - 10:45 AM CDT	Speaker	Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial Michael Levy, MD, PhD, FAAN
10:45 AM - 11:00 AM CDT	Speaker	The Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (ICECAP) Trial William J. Meurer, MD
11:00 AM - 11:15 AM CDT	Speaker	Factor XIa Inhibition with Asundexian in Acute Non-cardioembolic Stroke or High-risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial Mike Sharma, MD

Faculty Disclosures
Michael Levy, MD, PhD, FAAN	Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.
Kinga Tomczak, MD, PhD	Dr. Tomczak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Tomczak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Emalex Biosciences, Inc.. Dr. Tomczak has received personal compensation in the range of $0-$499 for serving as a Consultant for Frazier Life Sciences. Dr. Tomczak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Tomczak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Tomczak has received personal compensation in the range of $0-$499 for serving as a Consultant for Health Advances. Dr. Tomczak has received personal compensation in the range of $0-$499 for serving as a Consultant for Alpha Sights. Dr. Tomczak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Expert Connect. Dr. Tomczak has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex Biosciences, Inc.. The institution of Dr. Tomczak has received research support from Emalex Biosciences, Inc.. The institution of Dr. Tomczak has received research support from Noema Pharma.
Mike Sharma, MD	Dr. Sharma has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bayer. Dr. Sharma has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Regeneron. Dr. Sharma has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anthos. Dr. Sharma has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. The institution of Dr. Sharma has received research support from Bayer.
William J. Meurer, MD	Dr. Meurer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Berry Consultants. The institution of Dr. Meurer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Meurer Consulting. Dr. Meurer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Emergency Medicine. Dr. Meurer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Trials Journal (Springer Nature). Dr. Meurer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Academic Emergency Medicine Journal. Dr. Meurer has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Meurer Consulting. The institution of Dr. Meurer has received research support from NIH and AHRQ. Dr. Meurer has received personal compensation in the range of $500-$4,999 for serving as a Reviewer of Grants and FDA submissions with NIH and FDA. Dr. Meurer has a non-compensated relationship as a Member of Board of Directors with Society for Clinical Trials that is relevant to AAN interests or activities.
H. E. Hinson, MD, MCR, FAAN	Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association.
Jill M. Farmer, DO, MPH	Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Supernus. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acadia. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. Dr. Farmer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amneal. Dr. Farmer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Live. The institution of Dr. Farmer has received research support from Parkinson's Foundation.
Amy T. Waldman, MD	Dr. Waldman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio. An immediate family member of Dr. Waldman has or had stock in Pfizer. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Roche/Genentech. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Calico. Dr. Waldman has received publishing royalties from a publication relating to health care. Dr. Waldman has received publishing royalties from a publication relating to health care.
Vijay K. Ramanan, MD, PhD, FAAN	The institution of Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Daridorexant trial for AD prevention (funded by Weston Family Foundation). The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. The institution of Dr. Ramanan has received research support from ADLM (webinar supported by educational grant from Roche). The institution of Dr. Ramanan has received research support from American College of Radiology. Dr. Ramanan has received research support from Clinical Care Options. Dr. Ramanan has received research support from PeerView Institute (webinar supported by educational grant from Lilly). Dr. Ramanan has received personal compensation in the range of $5,000-$9,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Tuan H. Vu, MD	Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dianthus. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen (Horizon). Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VOR. Dr. Vu has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Johnson & Johnson. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Alexion. The institution of Dr. Vu has received research support from RA Pharma/UCB. The institution of Dr. Vu has received research support from ARGENX. The institution of Dr. Vu has received research support from Horizon/Amgen. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Cartesian Therapeutics. The institution of Dr. Vu has received research support from Janssen/Johnson & Johnson. The institution of Dr. Vu has received research support from Immunovant. The institution of Dr. Vu has received research support from Regeneron. The institution of Dr. Vu has received research support from Dianthus. The institution of Dr. Vu has received research support from COUR. The institution of Dr. Vu has received research support from NMD Pharma. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Faculty with AcademicCME. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Faculty with CMEO. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Faculty with PER. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Faculty with MedLive.
Pablo Villoslada, MD, PhD, FAAN	Dr. Villoslada has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oculis. Dr. Villoslada has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bionure. Dr. Villoslada has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Telara Therapeutics. Dr. Villoslada has or had stock in Attune Neurosciences.Dr. Villoslada has or had stock in Bionure Therapeutics.Dr. Villoslada has or had stock in Spiral Therapeutics.Dr. Villoslada has or had stock in Adhera Health.Dr. Villoslada has or had stock in Clarity technologies.Dr. Villoslada has or had stock in QMENTA Inc. The institution of Dr. Villoslada has received research support from Start2Cure Foundation. The institution of Dr. Villoslada has received research support from European Commission. The institution of Dr. Villoslada has received research support from Instituto Salud Carlos III. The institution of Dr. Villoslada has received research support from Focused Ultrasound Foundation and ALS Foundation. The institution of Dr. Villoslada has received research support from Caixa Foundation. Dr. Villoslada has received intellectual property interests from a discovery or technology relating to health care.